knowledge -WSS

knowledge

author：leisure time 2025-09-28 23:29:36 - browse：18951

Eli Lilly said Friday it will acquire Versanis Bio, a private company developing an obesity drug that specifically targets fat mass, as the race among pharmaceutical companies to offer weight loss medications intensifies.

The deal indicates Lilly is aiming to diversify its growing portfolio of weight loss therapies, as Versanis’ drug employs an entirely different mechanism than the existing obesity drugs that Lilly is studying. The pharma giant didn’t say how much it would pay Versanis upfront, but said that if the drug meets certain milestones, the total payment could reach $1.9 billion.

Lilly, along with other pharma companies like Novo Nordisk, has been developing products in the class of GLP-1 drugs, which mimic the glucagon-like peptide 1 hormone that helps people feel full. These drugs – including Novo’s Ozempic and Wegovy, and Lilly’s Mounjaro – have exploded in popularity because they lead to significant weight loss.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： How one patient went off dialysis — and others can too

Wikipedia

WSS

Would Medicare drug price negotiations stall in a shutdown?

Covid hospitalizations on the rise, Humana says

Covid hospitalizations on the rise, Humana says

How generative AI is inspiring dreams of a health data revolution

Amazon on where the company's health care bets are headed next

ALS advocates say criticism of new drugs misses bigger picture

hotspot

knowledge

explore

Malaria cases in Florida and Texas: Here’s what you need to know

'Make People Better': The CRISPR babies story you probably don't know

In age of alternative facts, a scholarly course on calling out crap

Kaiser Permanente unions announce official strike date

Virginia high school admissions case could be legal follow

'Make People Better': The CRISPR babies story you probably don't know

Trump demands the U.S. pay no more for drugs than other countries … again

Health tech startups drop sharply from 2021 highs

Affirmative action in medical school literally saved lives

FDA advisers vote against ALS treatment from BrainStorm

Wikipedia

House transparency, PBM reform bill gains bipartisan support

Menendez indictment could see pharma lose a key ally

Listen: Who gets the credit for GLP

Medicaid, Medicare dual

AstraZeneca chief proposes a novel edit to the drug pricing bill

The (many) problems with a new study criticizing cancer screening

entertainment

focus

Wikipedia

explore